According to Zhitong Finance App, Shiyao Group (01093.HK) announced that an open, multi-center phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics and initial efficacy of SYS6043 (B7-H3-ADC) single drug or combination bevacizumab and/or chemotherapy developed by the Group in advanced solid tumor participants has been officially launched at the first center in China.

Zhitongcaijing · 2d ago
According to Zhitong Finance App, Shiyao Group (01093.HK) announced that an open, multi-center phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics and initial efficacy of SYS6043 (B7-H3-ADC) single drug or combination bevacizumab and/or chemotherapy developed by the Group in advanced solid tumor participants has been officially launched at the first center in China.